Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pegfosimer manganese
- Development stage
- Phase 2
- Lead developer
- Spago Nanomedical
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Pegfosimer manganese is a novel, lesion-selective magnetic resonance imaging (MRI) contrast agent developed to enhance the visualization of soft tissue lesions such as those found in endometriosis and solid tumors. It consists of polymer nanoparticles loaded with manganese ions, designed for selective accumulation in pathological tissues due to their unique physiological properties. The agent provides clinically relevant MRI contrast enhancement with an acceptable safety profile demonstrated in phase I and IIa clinical studies. Pegfosimer manganese has shown particular promise for improving the precision of MRI-based detection and staging of endometriosis and breast cancer lesions. Its mechanism relies on enhancing MRI signal intensity by acting as a T1-weighted contrast enhancer through its paramagnetic properties[1][2][5][7].
- Brand names
- SpagoPix
- Other names
- pegfosimer manganeseSN132DSN-132DSN 132DSpagoPix
Beyond the preview
Go deeper on pegfosimer manganese.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pegfosimer manganese.